

Correction: Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

In this article (Cancer Prev Res 2013;6:1242–50), which was published in the November 2013 issue of *Cancer Prevention Research* (1), some of the values presented in Table 3 were incorrect due to a coding error in the analysis. The corrected Table 3 and the corresponding Results section with the correct values are below.

Table 3. HPV16 and HPV18 antibody stability between months 24, 36, and 48 by number of doses

	1-dose	2-doses _(0/1)	2-doses _(0/6)	3-doses	P-value
24–48 months <i>n</i> (%)					
HPV16 ^a					
Stable ^c	68 (87.18)	128 (91.43)	43 (82.69)	106 (88.33)	0.30
Decrease ^c	10 (12.82)	12 (8.57)	9 (17.31)	14 (11.67)	
HPV18 ^b					
Stable	71 (91.03)	128 (91.42)	43 (82.69)	103 (85.83)	0.24
Decrease	7 (8.97)	12 (8.57)	9 (17.31)	17 (14.17)	
36–48 months <i>n</i> (%)					
HPV16					
Stable decrease	74 (94.87)	136 (97.14)	51 (98.08)	117 (97.50)	0.69
	4 (5.13)	4 (2.86)	1 (1.92)	3 (2.50)	
HPV18					
Stable	72 (92.31)	134 (95.71)	51 (98.08)	118 (98.33)	0.15
Decrease	6 (7.69)	6 (4.29)	1 (1.92)	2 (1.67)	

^aHPV16 Spearman's rank correlation coefficient at 24- and 48-month visits was 0.88 ($P < 0.0001$).

^bHPV18 Spearman's rank correlation coefficient at 24- and 48-month visits was 0.90 ($P < 0.0001$).

^cStable antibodies defined as levels that did not decline by 2-fold or more; a decrease in antibodies as those that declined 2-fold or more.

Results

HPV16 and HPV18 antibody durability between 24 to 48 and 36 to 48 months is shown in Table 3. By our definition of less than a 2-fold change, stability between 24 to 48 and 36 to 48 months was high in all dose groups (stability_{24–48 months} in the one dose group: HPV16 = 87%; HPV18 = 91%; stability_{36–48 months} in the one dose group: HPV16 = 95%; HPV18 = 92%; all P values > 0.05 compared with the other dose groups) and only a small proportion of women had a decline in antibody levels observed between 24 to 48 and 36 to 48 months regardless of number of doses.

In addition, the maximum values for HPV16, 3-dose, 90th percentiles were mistakenly presented in Table 1. The correct 90th percentiles are (in the order they appear in the table) below.

Enrollment: 47.32

1: 2,349.73

6: 2,409.74

12: 6,683.96

24: 2,978.55

36: 2,573.65

48: 1,808.36

Finally, in the footnote for Table 4, the cutoff for HPV16 neutralization was incorrect. The correct cutoff for HPV16 neutralization is 25.1.

The authors regret the errors.

Reference

1. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. *Cancer Prev Res* 2013;6:1242–50.

Published online January 7, 2016.

doi: 10.1158/1940-6207.CAPR-15-0373

©2016 American Association for Cancer Research.

Cancer Prevention Research

Correction: Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

Cancer Prev Res 2016;9:116-117.

Updated version Access the most recent version of this article at:
<http://cancerpreventionresearch.aacrjournals.org/content/9/1/116>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://cancerpreventionresearch.aacrjournals.org/content/9/1/116.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerpreventionresearch.aacrjournals.org/content/9/1/116>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.